| Symbol
| CAMKK2
| contributors: mct - updated : 08-03-2023
|
| HGNC name
| calcium/calmodulin-dependent protein kinase kinase 2, beta
|
| HGNC id
| 1470
|
| Other morbid association(s)
|
| Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
|---|
| tumoral
|
|
| --over
|
|
in gastric cancer and leads to progression  | | tumoral
|
|
|
| gain of function
| |
in hepatocellular carcinoma (HCC) and negatively correlated with HCC patient survival | |
| Susceptibility
|
to bipolar and psychiatric disorders |
| Variant & Polymorphism
SNP
| Single-Nucleotide Polymorphisms increasing the risk of bipolar and psychiatric disorders |
| 
|
Candidate gene
Marker
Therapy target
|
|
| System | Type | Disorder | Pubmed |
|---|
| cancer | reproductive | | |
| novel therapeutic target for sex hormone-regulated cancers | | neuromuscular | myopathy | | |
| CAMKK2 could serve as a potential target to treat patients with muscle injury or myopathies | | cancer | digestive | stomach | |
| CAMKK2 as a novel therapeutic target in gastric cancer | | cancer | digestive | liver | |
| CaMKK2 and CaMK4 may represent potential targets for hepatic cancer | | diabete | | | |
| CaMKK2 may be an attractive therapeutic target for combatting comorbidities associated with perturbed insulin signaling |
| | | |
|
| CaMKK2 null mice have increased adiposity and larger adipocytes than do wild-type mice, whereas energy balance is unchanged |